目的 探讨蒲地蓝消炎口服液联合罗红霉素治疗小儿急性化脓性扁桃体炎的临床疗效。方法 选取2017年9月-2019年9月在郑州大学附属儿童医院儿科住院治疗的急性化脓性扁桃体炎患儿116例为研究对象，随机分为对照组和治疗组，每组各58例。对照组饭前1 h或饭后4 h口服罗红霉素分散片，2.5 mg/（kg·次），2次/d。治疗组在对照组治疗基础上口服蒲地蓝消炎口服液，10 mL/次，3次/d。两组患儿均连续治疗7 d。观察两组患儿的临床疗效；记录患儿临床症状消失时间；比较治疗前后患儿血清白细胞介素6（IL-6）、IL-8、IL-1β、IL-18、肿瘤坏死因子α（TNF-α）、C反应蛋白（CRP）水平。结果 治疗后，治疗组总有效率96.55%，显著高于对照组81.03%（P<0.05）。治疗后，治疗组患儿咽痛消失时间、脓点消失时间、退热时间、扁桃体恢复正常时间均显著短于对照组（P<0.05）。治疗后，治疗组患儿血清IL-6、IL-1β、IL-18、TNF-α、CRP水平均较治疗前显著降低（P<0.05）；治疗后，治疗组这些炎性因子水平显著低于对照组（P<0.05）。治疗组不良反应发生率是6.89%，显著低于对照组的17.24%（P<0.05）。结论 蒲地蓝消炎口服液联合罗红霉素治疗小儿急性化脓性扁桃体炎具有较好的临床疗效，可有效缩短临床症状时间，降低炎性因子水平，具有一定的临床推广应用价值。

Objective To investigate the curative effect of Pudilan Xiaoyan Oral Liquid combined with roxithromycin in treatment of children with acute suppurative tonsillitis. Methods A total of 116 children with acute suppurative tonsillitis who were hospitalized in Children's Hospital Affiliated to Zhengzhou University from September 2017 to September 2019 were selected as the research objects. The patients were randomly divided into control group and treatment group with 58 cases in each group. Children in the control group were po administered with Roxithromycin Dispersible Tablets 1 hour before or 4 hours after meals, 2.5 mg/kg, twice daily. Children in the treatment group were po administered with Pudilan Xiaoyan Oral Liquid on the basis of treatment in the control group, 10 mL/time, three times daily. Both groups were treated continuously for 7 days. The clinical efficacy of the two groups was observed, and the disappearance time of clinical symptoms was recorded. The serum levels of interleukin 6 (IL-6), IL-8, IL-1, IL-18, tumor necrosis factor α (TNF-α), and C-reactive protein (CRP) were compared before and after treatment. Results After treatment, the total effective rate of the treatment group was 96.55%, significantly higher than that of the control group (81.03%, P<0.05). After treatment, the disappearance time of pharyngeal pain, pus point, the time for antipyretic fever and the restoration time of tonsils in the treatment group were significantly shorter than those in the control group (P<0.05). After treatment, the serum levels of IL-6, IL-1, IL-18, TNF-α, and CRP in the treatment group were significantly lower than those before treatment (P<0.05). After treatment, the level of these inflammatory factors in the treatment group was significantly lower than that in the control group (P<0.05). The incidence of adverse reactions in the treatment group was 6.89%, significantly lower than that in the control group (17.24%, P<0.05). Conclusion Pudilan Xiaoyan Oral Liquid combined with roxithromycin has good clinical effect in treatment of children with acute suppurative tonsillitis, and can effectively shorten the time of clinical symptoms, and can reduce the level of inflammatory factors, which has certain clinical application value.

R987

河南省医学科技攻关项目（2018020682）